Accordingly, targeted therapies for melanoma, aiming BRAFV600E/K-expressing tumours, have involved the use of the BRAF inhibitor, vemurafenib, which was approved by the Food and Drug Administration (FDA) for unresectable or stage IV melanomas [5]. Here, BRAF is linked to melanoma.